Type 2 diabetes is one of the fastest-growing health problems in the world. The condition develops when the body becomes resistant to insulin, the hormone that helps move sugar from the blood into cells.
Over time, high blood sugar can lead to serious complications, including heart disease, kidney failure, vision problems, and nerve damage. Many people with type 2 diabetes also struggle with excess weight, which can make blood sugar even harder to control.
Because of these challenges, researchers have been searching for treatments that can lower blood sugar and help people lose weight at the same time.
In recent years, medicines known as GLP-1 receptor agonists have emerged as some of the most effective options. These drugs mimic a natural hormone in the body that increases insulin release, reduces appetite, and helps people feel full for longer periods.
Although these medications have been highly successful, there are still practical problems. Most are given by injection, which can discourage some patients.
An oral version of semaglutide is available, but it comes with complicated instructions and must be taken under specific conditions. Scientists therefore continue to search for simpler and more convenient oral medicines.
A new experimental drug called elecoglipron may provide another option. Researchers presented new findings at the American Diabetes Association’s Scientific Sessions, and the results were published simultaneously in The Lancet.
The study was led by Dr. Vanita Aroda, Director of Diabetes Clinical Research in the Division of Endocrinology, Diabetes and Hypertension at Mass General Brigham. According to Dr. Aroda, carefully designed clinical trials are essential for determining whether new medications can provide safer and more effective treatment options for people living with diabetes.
The study, called SOLSTICE, was sponsored by AstraZeneca and enrolled 406 adults with type 2 diabetes from nine countries. Participants were randomly assigned to receive different doses of elecoglipron or a placebo. The researchers then followed them for 26 weeks.
The findings showed that elecoglipron significantly improved blood sugar control. Up to 89.6 percent of participants taking the drug reached an HbA1c level of 7 percent, which is the recommended blood sugar target for many adults with type 2 diabetes. In contrast, only 24.9 percent of participants taking placebo achieved this goal.
The medication also produced substantial weight loss. Nearly three-quarters of participants taking elecoglipron lost at least 5 percent of their body weight, while only about one-fifth of people in the placebo group achieved similar results.
Researchers found that the drug’s safety profile was generally consistent with other GLP-1 medications that are already available.
The meeting also featured another study led by Dr. Aroda. The REIMAGINE 1 trial tested CagriSema, a combination of cagrilintide and injectable semaglutide. This treatment also produced encouraging results, with up to 87 percent of participants reaching their blood sugar targets.
These studies demonstrate how quickly the field of diabetes care is changing. Scientists now understand that managing type 2 diabetes involves much more than simply lowering blood sugar. Effective treatments may also need to help people lose weight, improve overall metabolic health, and reduce the risk of long-term complications.
After reviewing the SOLSTICE findings, it is clear that elecoglipron has considerable potential. The drug produced meaningful improvements in both blood sugar control and body weight and may eventually provide a more convenient alternative to injectable treatments.
However, the study was relatively short and involved a limited number of participants. More research is necessary to determine whether the benefits remain strong over many years and whether any uncommon side effects emerge with long-term use.
Even so, the results suggest that oral GLP-1 medicines may soon become an increasingly important part of diabetes treatment and could make effective therapy easier to access for millions of people.
Source: Mass General Brigham.
